<DOC>
	<DOCNO>NCT00104819</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's cancer cell may make body build effective immune response kill cancer cell . Colony-stimulating factor , GM-CSF , may increase number immune cell find bone marrow peripheral blood may stimulate immune system different way stop cancer cell grow . PURPOSE : This phase II trial study well give vaccine therapy together GM-CSF work treat patient progressive B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Vaccine Therapy GM-CSF Treating Patients With Progressive Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Provide treatment autologous immunoglobulin idiotype-KLH conjugate vaccine ( FavId ) ™ sargramostim ( GM-CSF ) patient progressive grade 1 , 2 , 3 follicular B-cell non-Hodgkin 's lymphoma receive FavId™ enrol protocol FAV-ID-06 . Secondary - Determine response rate duration response patient treat regimen . - Determine response rate response rate improvement best response prior salvage therapy patient treat regimen . - Determine time progression patient treat regimen . - Determine safety regimen patient . OUTLINE : This multicenter study . Patients assign 1 2 group accord time disease progression enrol protocol FAV-ID-06 ( disease progression prior rituximab AND never randomize vs disease progression randomization placebo arm ) . Patients receive autologous immunoglobulin idiotype-KLH vaccine subcutaneously ( SC ) day 1 . Patients also receive sargramostim ( GM-CSF ) SC day 1-4 . Treatment repeat monthly 6 month absence disease progression unacceptable toxicity . Patients stable respond disease may receive additional treatment every 2 month 1 year ( 6 treatment ) every 3 month disease progression . After completion study treatment , patient follow 30 day start subsequent treatment . PROJECTED ACCRUAL : Approximately 238 patient ( 67 group I 171 group II ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin Idiotypes</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm follicular Bcell nonHodgkin 's lymphoma ( NHL ) Grade 1 , 2 , 3 Progressive disease AND receive autologous immunoglobulin idiotypeKLH conjugate vaccine ( FavId™ ) enrol protocol FAVID06 Meets 1 follow criterion : Received salvage therapy completion protocol FAVID06 At least 4 week , 4 month , since prior salvage therapy Did receive salvage therapy completion protocol FAVID06 At least 4 week , 4 month , since completion prior treatment protocol FAVID06 No history CNS lymphoma OR meningeal lymphomatosis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular No history congestive heart failure Pulmonary No history compromise pulmonary function Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No active bacterial , viral , fungal infection No psychiatric disorder No serious nonmalignant disease would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics No prior allogeneic transplantation* No prior rituximab regimen* administer protocol FAVID06 ( rituximab 375 mg/m^2 IV weekly 4 week ) Chemotherapy No prior purine analogues* ( e.g. , fludarabine cladribine ) Endocrine therapy No prior concurrent steroid ( e.g. , steroid dos excess daily replacement ) Radiotherapy Not specify Surgery Not specify Other Recovered prior salvage therapy No prior concurrent immunosuppressive therapy No prior investigational agents* No concurrent antilymphoma therapy NOTE : *As salvage therapy administer completion protocol FAVID06 enrollment onto study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
</DOC>